Article
Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patients
2022-03-30
Abstract excerpt
<h4>Introduction: </h4> Real-world data on Omalizumab (OMA) and Mepolizumab (MEPO) can inform their use in severe asthma (SA). We studied patients in the Wessex AsThma CoHort of difficult asthma (WATCH) to: 1. Phenotypically compare OMA or MEPO treated patients against a SA, non-biologic group (SNB). 2. Assess clinical responses to OMA and MEPO. 3. Assess the spectrum of responses to these biologics. Methods We re...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4af71478-c0f5-5fc7-9279-ec0c891ecbe1
- DOI
- 10.22541/au.164864374.43279903/v1
